| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(99)00272-8 |
| P698 | PubMed publication ID | 10547425 |
| P2093 | author name string | Garcia A | |
| Dumas R | |||
| Naveda O | |||
| Bordones G | |||
| Casanova de Escalona L | |||
| Castillo de Febres O | |||
| Chacon de Petrola M | |||
| Estopinan M | |||
| Naveda M | |||
| Zambrano B | |||
| P2860 | cites work | Epidemiological patterns of hepatitis A in different parts of the world | Q35237402 |
| Long-term immunogenicity and safety of an inactivated hepatitis A vaccine in haemophilic patients | Q38970499 | ||
| Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine | Q39206095 | ||
| Persistence of vaccine-induced antibody to hepatitis A virus | Q39591650 | ||
| Seroepidemiological investigation of patients and family contacts in an epidemic of hepatitis A | Q40135937 | ||
| Propagation of human hepatitis A virus in a hepatoma cell line | Q40295695 | ||
| Clinical development of a new inactivated hepatitis A vaccine | Q41328514 | ||
| An outbreak of hepatitis A in young adults in central Italy | Q42091619 | ||
| Vaccination against hepatitis A: control 3 years after the first vaccination | Q43892214 | ||
| Inactivated hepatitis A vaccine in childhood: implications for disease control | Q43939694 | ||
| Safety, tolerability and immunogenicity of a formalin-inactivated hepatitis A vaccine (VAQTA) in rural Kentucky children. | Q44351131 | ||
| Six years' follow-up after hepatitis A vaccination | Q44814987 | ||
| Safety and immunogenicity of an inactivated hepatitis A vaccine in children 2 to 5 years old. | Q45235063 | ||
| Persistence of vaccine-induced antibodies for hepatitis A virus | Q45781355 | ||
| Immunogenicity, safety and tolerability of varying doses and regimens of inactivated hepatitis A virus vaccine in Navajo children | Q45782203 | ||
| Vaccination against hepatitis A virus in French hemophilic children | Q45790612 | ||
| Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine. | Q53365701 | ||
| Protection against hepatitis A by an inactivated vaccine | Q56995443 | ||
| Immunogenicity and efficacy of a killed hepatitis A vaccine in day care center children | Q57109807 | ||
| A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children | Q57111592 | ||
| Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults | Q64135080 | ||
| Safety and immunogenicity of hepatitis A vaccine in healthy children | Q70464519 | ||
| Immunogenicity of inactivated hepatitis A vaccine in children | Q70634969 | ||
| Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study | Q71748623 | ||
| Immunogenicity and safety of a new inactivated hepatitis A vaccine: a clinical trial with comparison of administration route | Q71764067 | ||
| Good immunogenicity of GBM strain inactivated hepatitis A vaccine in healthy male adults | Q71932276 | ||
| Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children | Q72592863 | ||
| Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence | Q72646916 | ||
| Sensitive assays for hepatitis A antibodies | Q72663324 | ||
| Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study | Q73312616 | ||
| Response to Hepatitis A Vaccine in Children after a Single Dose with a Booster Administration 6 Months Later | Q77553160 | ||
| P433 | issue | 7-8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hepatitis A | Q157661 |
| hepatitis A vaccine | Q3553093 | ||
| P1104 | number of pages | 9 | |
| P304 | page(s) | 656-664 | |
| P577 | publication date | 1999-11-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children | |
| P478 | volume | 18 |
| Q35613375 | Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting |
| Q34787404 | Hepatitis A vaccines |
| Q44642735 | Interchangeability of a hepatitis A vaccine second dose: Avaxim 80 following a first dose of Vaqta 25 or Havrix 720 in children in Turkey |
| Q30890134 | Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation |
| Q58595656 | Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: a phase IV study |
| Q36738155 | Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study |
| Q90470441 | The how's and what's of vaccine reactogenicity |
| Q40118010 | The tolerability of a combined hepatitis A and typhoid vaccine in children aged 2-16 years: an observational study |
Search more.